Slingshot members are tracking this event:

Advisory Committee Meeting on October 12, 2017 for Spark Therapeutics (ONCE) Voretigene neparvovec (SPK-RPE65) in treating vision loss due to confirmed biallelic RPE65 mutation-associated retinal dystrophy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
ONCE Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 12, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda Ad-comm, Voretigene Neparvovec, Spk-rpe65, Vision Loss, Biallelic Rpe65 Mutation, Retinal Dystrophy